I get it is just an AIM, but given this was presented only yesterday one would think it is seen as an achievable AIM. If hit it would suggest a read out before the end of 2024 and certainly no later than the very start of 2025. This would be a good 6 to 9 months ahead of where I was expecting us to be.
Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial, page-15
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 72081 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 10.04am 17/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable